https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01755-4/fulltext

Posted in Uncategorized | Comments Off on 1-year outcomes in hospital survivors with COVID-19

Abstract
Fluvoxamine, an SSRI and sigma-1 receptor agonist, has so far shown promise in the prevention of COVID-19 progression as an early treatment option in 3 conducted trials. The aim of this study was to evaluate the safety and efficacy of fluvoxamine in COVID-19 patients if administered later in the disease’s course.

The study was designed as an open label, prospective cohort trial with matched controls. In April and May 2021, 51 ICU COVID-19 patients hospitalised in the University Hospital Dubrava and University Hospital Centre Zagreb, Croatia, were treated with fluvoxamine 100mg three times daily for 15 days in addition to standard therapy and they were prospectively matched for age, gender, vaccination against COVID-19, disease severity and comorbidities with 51 ICU controls.

No statistically significant differences between groups were observed regarding the number of days on ventilator support, duration of ICU or total hospital stay. However, overall mortality was lower in the fluvoxamine group, 58.8% (n=30/51), than in the control group, 76.5% (n=39/51).

The authors concluded that fluvoxamine treatment in addition to the standard therapy could have a positive impact on patient survival. Further studies on the effects of fluvoxamine in COVID-19 patients are required.

Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, Likic R. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol. 2021 Nov 1. doi: 10.1111/bcp.15126. Epub ahead of print. PMID: 34719789.

https://pubmed.ncbi.nlm.nih.gov/34719789/

 

Posted in Uncategorized | Comments Off on Safety and efficacy of fluvoxamine in COVID-19 ICU patients

Di Pietro M et al., Covid-19 related stroke: No preventative value of antithrombotic therapy.  Journal of the Neurological Sciences 429, Supplement: 117659, October 1, 2021.  DOI:https://doi.org/10.1016/j.jns.2021.117659

https://www.jns-journal.com/article/S0022-510X(21)00353-1/fulltext

https://www.medscape.com/viewarticle/961323

 

Posted in Uncategorized | Comments Off on Covid-19 related stroke: No preventative value of antithrombotic therapy

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500775/

Posted in Uncategorized | Comments Off on Rapid response to selective serotonin reuptake inhibitors in post-COVID depression

Agha H, McCurdy CR. In vitro and in vivo sigma 1 receptor imaging studies in different disease states. RSC Med Chem. 2021 Oct 8;12(2):154-177. doi: 10.1039/d0md00186d. PMID: 34046607; PMCID: PMC8127618.

https://pubmed.ncbi.nlm.nih.gov/34046607/

Posted in Uncategorized | Comments Off on In vitro and in vivo sigma 1 receptor imaging studies in different disease states

Alopecia areata (AA) is an autoimmune disorder that usually results in unpredictable, patchy hair loss. It is associated with multiple comorbidities and shares a similar inflammatory signature with dementia. The great negative psychosocial impact of AA may result in poor social engagement, a typical risk factor for dementia. However, little is known about the association between AA and dementia. 

Patients with AA were more likely to develop any dementia, and unspecified dementia than the control cohort. Stratification analysis by age and sex revealed increased risks of any dementia and unspecified dementia in both age groups (ie, < 65 and ≥ 65 years) and both sex groups and increased risks of AD in male patients and in those with age at dementia onset ≥ 65 years. Sensitivity analyses after exclusion of the first year or first 3 years of observation showed consistent findings.

In summary, patients with AA had a higher risk of developing dementia. Further studies are needed to elucidate the underlying pathophysiology between AA and dementia risk.

Li CY, Tai YH, Dai YX, Chang YT, Bai YM, Tsai SJ, Chen TJ, Chen MH. Association of Alopecia Areata and the Risk of Dementia: A Nationwide Cohort Study. J Clin Psychiatry. 2021 Oct 26;82(6):21m13931. doi: 10.4088/JCP.21m13931. PMID: 34705346.

https://pubmed.ncbi.nlm.nih.gov/34705346/

Posted in Uncategorized | Comments Off on Association of Alopecia Areata with increased Risk of Dementia

Abstract:  “The Sigma-1 receptor (S1R) is an endoplasmic reticulum (ER) chaperone protein that has been implicated in attenuating inflammatory stress-mediated brain injuries. Selective S1R agonists represent a new class of therapeutic agent for treating neuropsychiatric and neurodegenerative disorders, however, to date, no S1R ligand has been approved for therapeutic purposes. We used three potential methods on known and potential S1R ligands to develop an unambiguous high-throughput cell screen for S1R activity. We screened known and potential S1R ligands using radioligand binding and previously reported markers of S1R activity including BDNF release, modulation of IP3 mediated calcium release, and modulation of NGF-induced neurite sprouting. Here, we present results several prototypical S1R compounds and some compounds with the potential for drug repurposing. Using an in-situ ELISA approach we demonstrated that these compounds could stimulate S1R-mediated BDNF release, which is a valuable therapeutic property since BDNF plays a critical role in neuronal support. These compounds were classified as S1R agonists because the BDNF response was comparable to the prototypical agonist 4-PPBP and because it could be reversed by a S1R selective concentration of the antagonist BD1063. When modulation of IP3 mediated calcium response and NGF-induced neurite sprouting were used as a measure of S1R activation, we were unable to reproduce the published results and determined that they are not reliable measures for evaluating functional properties of S1R ligands.”

Dalwadi DA, Kim S, Schetz J, Schreihofer DA, Kim S. Brain-derived neurotrophic factor for high-throughput evaluation of selective Sigma-1 receptor ligands. J Pharmacol Toxicol Methods. 2021 Oct 20:107129. doi: 10.1016/j.vascn.2021.107129. Epub ahead of print. PMID: 34678430.

https://pubmed.ncbi.nlm.nih.gov/34678430/

 

Posted in Uncategorized | Comments Off on Brain-derived neurotrophic factor for high-throughput evaluation of selective Sigma-1 receptor ligands

https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext

Posted in Uncategorized | Comments Off on Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19

Shi M, Chen F, Chen Z, Yang W, Yue S, Zhang J, Chen X. Sigma-1 Receptor: A Potential Therapeutic Target for Traumatic Brain Injury. Front Cell Neurosci. 2021 Sep 30;15:685201. doi: 10.3389/fncel.2021.685201. PMID: 34658788; PMCID: PMC8515188.

https://pubmed.ncbi.nlm.nih.gov/34658788/

Posted in Uncategorized | Comments Off on Sigma-1 Receptor: A Potential Therapeutic Target for Traumatic Brain Injury


“In conclusion, at present it is unclear whether a Sig-1R agonist or Sig-1R antagonist would be better for inhibiting SARS-CoV-2 replication. Experiments comparing these ligands in the same assay are warranted. Until then, classifying anti- inflammatory anaesthesia drugs such as dexmedetomidine21 as ‘pro-viral’ based on their agonistic activity on Sig-1R is not supported by evidence.”

Jain A, Lamperti M, Doyle DJ, Lobo FA. Anaesthesia drugs, SARS-CoV-2, and the sigma-1 receptor: a complex affair. Comment on Br J Anaesth 2021; 127: e32-4. Br J Anaesth. 2021 Sep 20:S0007-0912(21)00579-1. doi: 10.1016/j.bja.2021.09.008. Epub ahead of print. PMID: 34635287; PMCID: PMC8500736.

https://pubmed.ncbi.nlm.nih.gov/34635287/

Posted in Uncategorized | Comments Off on Anesthesia drugs, SARS-CoV-2, and the sigma-1 receptor: a complex affair